Clareo Health | Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ECOG Performance Status (PS) ≤1
Histologically or cytologically confirmed, unresectable metastatic colorectal cancer
Measurable disease by RECIST guidelines
Evidence of disease progression following first-line therapy with a fluoropyrimidine, oxaliplatin, and bevacizumab (≤ 8 weeks since last dose)
Available paraffin embedded tumor tissue
Willing to give a whole blood sample for the study of proteins and genetic polymorphisms
You may not be if
Less than 28 days elapsed since major surgery at time of randomization
Known CNS metastases
Excessive risk of bleeding (including use of therapeutic anticoagulation other than low dose aspirin) and history of thrombotic or embolic cerebrovascular accident
Uncontrolled hypertension
Clinically significant cardiovascular disease
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis
